Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer

Published:2005-06-14 Issue:1 Volume:93 Page:29-34
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Cappuzzo F,Novello S,De Marinis F,Franciosi V,Maur M,Ceribelli A,Lorusso V,Barbieri F,Castaldini L,Crucitta E,Marini L,Bartolini S,Scagliotti G V,Crinò L

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6602667.pdf

Reference38 articles.

1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535–1540

2. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821–1826

3. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623–631

4. Bunn Jr PA, Lilenbaum R (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 95: 341–343

5. Castellano D, Lianes P, Paz-Ares L, Hidalgo M, Guerra JA, Gomez-Martin C, Gomez H, Calzas J, Cortes-Funes H (1998) A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol 9: 457–459

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hapten Improved Overall Survival Benefit in Late Stages of Non-Small Cell Lung Cancer (NSCLC) by Ultra-Minimum Incision Personalized Intratumoral Chemo Immunotherapy (UMIPIC) Therapy With and without Radiation Therapy;Journal of Cancer Prevention & Current Research;2016-02-08

2. Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy;Lung Cancer: Targets and Therapy;2015-01

3. Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer;Thoracic Cancer;2014-10-23

4. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC);Cancer Chemotherapy and Pharmacology;2013-09-22

5. A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer;British Journal of Cancer;2013-01-17